Pfizer, Sanofi-Aventis, Novartis, GlaxoSmithKline, Abbott Laboratories and Merck to Speak at the 9th Polymorphism &

PHILADELPHIA--(BUSINESS WIRE)-- There has been increased focus on using crystals and the ever-changing, sometimes disappearing properties of polymorphs as significant scientific and business opportunities. IQPC’s Polymorphism & Crystallization Scientific Forum, taking place October 25- 27, 2010 in Philadelphia, PA will address these issues.

Attendees will hear the latest pharmaceutical research and scientific advances for polymorphism and crystallization. Topics to be discussed at the event include:

  • Polymorphism patent procurement and protection
  • Developing new strategies to extend product lifecycles
  • Improving pharmaceuticals through co-crystals
  • Positioning R&D teams to deliver more timely solutions
  • Using Innovative analysis techniques to assure quality along the path to development
  • Tablet sticking and picking

The audience for this event comprises of professionals specializing in chemistry, sciences, chemical engineering, physical properties, pre-formulation, drug delivery, pharmaceutics, solid state and toxicology.

Plus, attendees have the opportunity to attend three pre-conference workshops on the following topics:

  • Crystal phase screening, selection and optimization in early stage drug development
  • Emergence of new crystal phases during late stage development: impact, management prevention
  • Polymorphism as a tool for life cycle extension

The speaker faculty for this event includes: Pfizer, Novartis, Abbott Laboratories, Astrazeneca, GlaxoSmithKline, University of Michigan, Vertex Pharmaceuticals and more.

For more information, visit the website or contact Karen Richardson at [email protected] or (646) 378-6034.

IQPC produces more than 1,500 events annually around the world, and continues to grow. Founded in 1973, IQPC now has offices in major cities across five continents. IQPC leverages a global research base of best practices to produce a cross industry of information-sharing forums.



CONTACT:

IQPC
Karen Richardson, 646-378-6034
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Other Science  Science

MEDIA:

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.